Goldman Sachs Group reissued their buy rating on shares of Relx (LON:REL) in a research note published on Tuesday, Borsen Zeitung reports.
REL has been the topic of a number of other reports. Deutsche Bank decreased their price objective on Relx from GBX 1,925 ($23.69) to GBX 1,850 ($22.77) and set a hold rating on the stock in a report on Friday, July 3rd. Liberum Capital restated a buy rating on shares of Relx in a research report on Wednesday, April 8th. Credit Suisse Group set a GBX 2,010 ($24.74) price target on Relx and gave the company a buy rating in a report on Friday, June 19th. BNP Paribas downgraded shares of Relx to an underperform rating and dropped their price objective for the stock from GBX 1,900 ($23.38) to GBX 1,650 ($20.31) in a report on Tuesday, June 30th. Finally, UBS Group restated a neutral rating and set a GBX 1,790 ($22.03) target price (down previously from GBX 1,790 ($22.03)) on shares of Relx in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of GBX 1,953.67 ($24.04).
LON:REL opened at GBX 1,810 ($22.27) on Tuesday. The business’s 50-day moving average price is GBX 1,881.29 and its two-hundred day moving average price is GBX 1,868.30. Relx has a twelve month low of GBX 1,382.86 ($17.02) and a twelve month high of GBX 2,109 ($25.95). The stock has a market cap of $34.90 billion and a P/E ratio of 23.50. The company has a quick ratio of 0.33, a current ratio of 0.41 and a debt-to-equity ratio of 293.11.
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.